Evogene Ltd. (EVGN) stock
EVGNNasdaqAgricultural ChemicalsFiscal year ends December 31
$0.36−0.03 (-8.70%)
Close on Nov 12, 2026Market cap $3.15MP/E 0.3Yield –
Evogene r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $7.99M, down 36.1% from the year before. Over ten years it grew -5.7% a year on average. The highest annual figure on record is $21.13M in fiscal 2021.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $7.99M | -36.1% |
| FY2024 | Dec 31, 2024 | $12.51M | -22.8% |
| FY2023 | Dec 31, 2023 | $16.20M | -22.1% |
| FY2022 | Dec 31, 2022 | $20.79M | -1.6% |
| FY2021 | Dec 31, 2021 | $21.13M | +22.2% |
| FY2020 | Dec 31, 2020 | $17.29M | +9.5% |
| FY2019 | Dec 31, 2019 | $15.79M | +7.5% |
| FY2018 | Dec 31, 2018 | $14.69M | -13.5% |
| FY2017 | Dec 31, 2017 | $16.99M | +3.5% |
| FY2016 | Dec 31, 2016 | $16.41M | +13.5% |
| FY2015 | Dec 31, 2015 | $14.45M | – |
See a number that looks wrong?